Canada · Seed startup

Who invested in SignPost Cancer Dx

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 26 Oct 2026

$250Kraised across 1 round since 2023, from 1 source

Latest round
Seed, $250KJan 2023
Investors
1
See who backed them

The rounds

  1. Jan 2023
    Seed$250K

    Source recorded

Founders and team

From SignPost Cancer Dx's own website: 3 founders, 8 on the team.

Peter BlaneyCEO And Founder, Director
Nicol McNicolCo-Founder And Director
Ryan SmithCo-Founder And Director
  • Adam MarshChief Product Officer
  • Ashley DoaneChief Computational Biologist
  • David W. JaffinChief Financial Officer
  • David WilsonChief Commercialization Officer
  • Jeb ConnorChairman
  • Lee McCrackenDirector
  • Nicholas DracopoliDirector
  • Rajen DalalDirector

Everyone who backed them

Newchip AcceleratorAccelerator1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about SignPost Cancer Dx

Who invested in SignPost Cancer Dx?

SignPost Cancer Dx's investors include Newchip Accelerator.

How much has SignPost Cancer Dx raised?

SignPost Cancer Dx has raised $250K across 1 round since 2023.

When did SignPost Cancer Dx last raise?

SignPost Cancer Dx's most recent round was a Seed of $250K in Jan 2023.

What was SignPost Cancer Dx's biggest round?

Its most recent round, $250K in Jan 2023, is also its largest on record.

Who backed SignPost Cancer Dx first?

SignPost Cancer Dx's first round on record, in Jan 2023, was backed by Newchip Accelerator.

What stage is SignPost Cancer Dx at?

SignPost Cancer Dx's latest named round is a Seed, in Jan 2023.

Where is SignPost Cancer Dx based?

SignPost Cancer Dx is based in Canada.

Companies like SignPost Cancer Dx

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.